Abstract
Abstract
Background
5-Fluorouracil (5-FU) remains a core component of systemic therapy for colorectal cancer (CRC). However, response rates remain low, and development of therapy resistance is a primary issue. Combinatorial strategies employing a second agent to augment the therapeutic effect of chemotherapy is predicted to reduce the incidence of treatment resistance and increase the durability of response to therapy.
Methods
Here, we employed quantitative proteomics approaches to identify novel druggable proteins and molecular pathways that are deregulated in response to 5-FU, which might serve as targets to improve sensitivity to chemotherapy. Drug combinations were evaluated using 2D and 3D CRC cell line models and an ex vivo culture model of a patient-derived tumour.
Results
Quantitative proteomics identified upregulation of the mitosis-associated protein Aurora B (AURKB), within a network of upregulated proteins, in response to a 24 h 5-FU treatment. In CRC cell lines, AURKB inhibition with the dihydrogen phosphate prodrug AZD1152, markedly improved the potency of 5-FU in 2D and 3D in vitro CRC models. Sequential treatment with 5-FU then AZD1152 also enhanced the response of a patient-derived CRC cells to 5-FU in ex vivo cultures.
Conclusions
AURKB inhibition may be a rational approach to augment the effectiveness of 5-FU chemotherapy in CRC.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J cancer. 2019;144:2992–3000.
2. World cancer research fund international. colorectal cancer statistics: world cancer research fund international; 2022 [Available from: https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/.
3. American society of clinical oncology. colorectal cancer statistics: American society of clinical oncology; 2022 [Available from: https://www.cancer.net/cancer-types/colorectal-cancer/statistics.
4. Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2023;20:306–22 https://doi.org/10.1038/s41575-022-00736-1.
5. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.